I n mystery writings, the classification of a "whodunit" refers to a story in which the puzzle of who committed the crime is the main feature of interest. In a somewhat comparable manner, interrogations into the local control of blood flow can be construed as chapters of a physiological whodunit mystery-of course, with the hope that the science is nonfictional! For the physiological whodunit, the cast of characters consists of the myriad factors involved in the local control of blood flow, including adenosine, nitric oxide, hydrogen peroxide, and ATP, to name a few.
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The specific factors responsible for the local control of blood flow have eluded unequivocal identification. Perhaps this difficulty relates to the likely possibility that there are redundant local control mechanisms that regulate flow, so that when one system is blocked, another can assume control. Another complication is that local control of flow is related to many different conditions, including changes in tissue oxygen demands, ischemia, hypoxia, changes in intravascular pressure, and changes in shear stresses, and these myriad factors introduce a highly complicated system that likely follows nonlinear dynamics, at least in the heart. 1 In this issue of Circulation Research, Kirby et al 2 have added a chapter in the whodunit mystery by suggesting that the intravascular production of ATP contributes to dilation in skeletal muscle during systemic hypoxia and active (exercise-induced) hyperemia in humans. The authors further suggest that diminished ATP release by red cells in aged individuals contributes to the hampered vasodilatory responses to hypoxia and increased muscle metabolism observed in older persons. This clinical study appears to be well done, and there appear to be no issues with the results. However, we are skeptical of the conclusions, in part because of limitations in the experimental design and assumptions that open the conclusions to other interpretations. Before we expound on these issues, it is useful to succinctly review some concepts regarding local metabolic control of flow.
The observations of Kirby et al 2 were founded on previous reports suggesting that the release of ATP by red cells, during local deoxygenation of blood, contributes to the regulation of blood flow in skeletal muscle, lung, and heart. [3] [4] [5] [6] [7] [8] [9] In this paradigm, the release of ATP during local hypoxia in capillaries induces a response that propagates vasodilatory signals upstream to resistance vessels. A schematic of this cascade is shown in the Figure (sequence on the left). In this hypothetical sequence, conditions that decrease PO 2 in capillaries (increased oxygen consumption of parenchymal cells, decreased oxygen delivery, systemic hypoxia) induce the release of ATP from red cells. ATP then promotes purinergic vasodilation of arterioles via the propagated mechanism mentioned previously. Propagation of the vasodilatory signal is deemed necessary because capillary PO 2 would be lower than that in arterioles; thus, more ATP would be released from red cells in capillaries (although longitudinal gradients in PO 2 across capillaries have been documented previously 10 ). In contrast, a more conventional scheme for local metabolic vasodilation is shown as the sequence on the right in the Figure. In this example, parenchymal cells, not red cells, drive the process of local vasodilation. Moreover, parenchymal cells, not red cells, are the "sensors" that drive flow control via the production of metabolic dilators. It is well established that parenchymal cells (eg, skeletal muscle myocytes and cardiac myocytes) produce metabolic vasodilators that directly influence smooth muscle tone.
In the Figure, the area highlighted in blue shows the important differences between the 2 schemes, which primarily relate to the source of the metabolic signal and have 
Figure. Two different schemes for metabolic dilation. Left,
The hypothetical sequence of events in which ATP release from red blood cells mediates local metabolic dilation to increased oxygen consumption or hypoxia. Right, The sequence of events involving the production of a metabolic dilator by the tissue via changes in oxygen consumption or hypoxia. The blue highlighted area represents the major differences between the 2 schemes, with the dilator produced either by red cells or by the parenchymal tissue.
important implications in the feedback control of blood flow. In the model suggested and supported by Kirby et al, 2 the red cell production of ATP is central to metabolic dilation, whereas in the more conventional model of metabolic dilation, parenchymal tissue production of the metabolic signal is critical. This is another issue that foments our skepticism that red cells are key regulators of metabolic and hypoxic dilation. For example, isolated cardiac myocytes, when stimulated electrically, show a large increase in oxygen consumption and the production of metabolic vasodilators, as demonstrated in a bioassay preparation of arteriolar vasoactivity. [11] [12] [13] In this situation, there are no red cells, but robust dilation from the production of metabolites by working myocytes (electrically stimulated) was observed. Kirby and colleagues 2 could argue that the skeletal muscle circulation, which they studied, is vastly different from the coronary circulation, and we would accept part of that argument. However, we opine that their observations do not unequivocally show the role of ATP release by red cells as a mechanism of vasodilation.
There are several key issues that fuel this skepticism. First, a critical omission was the lack of evidence showing that an antagonist of purinergic receptors would prevent the vasodilation. In fairness, the authors discuss this problem by stating that no such antagonist is available for patient studies. Nonetheless, this constitutes a deficiency in the study and detracts from the conclusions. Second, the increase in venous blood concentration of ATP is clearly significant, but is this of sufficient magnitude to produce a vasodilatory effect? It is hard to equate the amount of ATP produced by a certain number of red cells in vitro to the in vivo situation. Third, an increase in venous concentration of ATP may result from ATP release by skeletal muscle and not red cells. We realize this would be difficult to test in patients, but nonetheless, a rise in venous concentration of any substance may be the result of enhanced production by working muscle. This untested assumption, in all in vivo studies proposing this hypothesis, is a serious limitation. Finally, the results are purely correlational, ie, with increased metabolism, venous levels of ATP rise. This forms one basis for the conclusions, but one could make a similar plot with a reduction in venous PO 2 showing an inverse relationship, or perhaps with a rise in venous pCO 2 . These, too, would likely show good correlations but may not indicate the true causal control mechanism. We understand the limitations inherent in studying human subjects, work that obviously has unique significance over experimental animal studies, but the fact remains that the data showing the production of ATP resulting from increased work are purely correlational. This can imply a causal relationship but does not prove it.
Kirby et al 2 also show that ATP is released by red cells in samples of blood subjected to hypoxia, and they also observed differences between old and young patients. These are important results that provide plausibility for the authors' conclusions, yet we wonder whether the release of ATP by working skeletal muscle would also be different in young versus old patients. Perhaps this is a generalized mechanism of aging and does not necessarily imply an altered control mechanism by red cells.
In summary, we wish to compliment the authors on an interesting and provocative study. As mentioned previously, we hold the opinion that the data are sound, but because of concerns described above, we have a very different conclusion. We have asked ourselves, what type of evidence would it take to convince us that the release of ATP from red cells plays an important role in metabolic dilation? We would like to see results from animal studies using chimeric models with red cells devoid of pannexin-1, which is thought be involved in ATP release from red cells. 14 If flow control was altered in this condition, there would be stronger evidence for the role of red cell release of this high-energy phosphate in metabolic vasodilation. We would like to challenge the authors, the readers, and others interested in the topic of metabolic control of flow to strengthen their experimental design and investigators-for all putative metabolic vasodilators-to bring this whodunit mystery to a better end.
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